Coverage from the 61st Annual ASH Meeting & Exposition: Focus on Multiple Myeloma
The 61st ASH Annual Meeting and Exposition will be held in Orlando, Fla., Dec. 7-10, 2019. Attendees will have access to thousands of scientific abstracts highlighting cutting-edge research in hematology. This conference is an opportunity to enhance your practice through educational programs while networking with leaders in the field. Check out highlights from the upcoming conferences to help you make the most of your time at ASH.
Results of an independent sequential patient cohort that indicated current clinical variables used to determine high risk (HR) in smoldering multiple myeloma (SMM) are not reliable were presented at the 2019 ASH Annual Meeting.
Results from the primary analysis of the phase II CANDOR study evaluating carfilzomib in combination with dexamethasone and daratumumab (KdD) compared to carfilzomib and dexamethasone alone (Kd) in patients with relapsed or refractory multiple myeloma were presented in a late-breaking abstract session at the 2019 ASH Annual Meeting
Data introducing an extensive platform in genetically-modified NK- and T cell-based programs, and highlighting long-term safety and efficacy results from the phase I study of PNK-007 in patients with multiple myeloma, were announced at the 2019 ASH Annual Meeting.
Join Oncology Times in Orlando! We are providing live updates on cutting-edge research throughout the conference. Follow us on Twitter (@OncologyTimes) and Facebook (@OncologyTimesNews) to learn about the latest hematology/oncology breakthroughs.